107 related articles for article (PubMed ID: 15890524)
1. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature.
Gadducci A; Cosio S; Conte PF; Genazzani AR
Crit Rev Oncol Hematol; 2005 Aug; 55(2):153-66. PubMed ID: 15890524
[TBL] [Abstract][Full Text] [Related]
2. Salvage chemotherapy for epithelial ovarian carcinoma.
Christian MC; Trimble EL
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S143-50. PubMed ID: 7835799
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
[TBL] [Abstract][Full Text] [Related]
5. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
6. Maintenance or consolidation therapy in advanced ovarian cancer.
Pectasides D; Pectasides E
Oncology; 2006; 70(5):315-24. PubMed ID: 17164587
[TBL] [Abstract][Full Text] [Related]
7. The use of paclitaxel and cisplatin in a patient with epithelial ovarian cancer and human immunodeficiency virus.
Knox SN; Robinson JB; Im DD; Logan L; Rosenshein NB
Gynecol Oncol; 2000 Jan; 76(1):118-22. PubMed ID: 10620453
[TBL] [Abstract][Full Text] [Related]
8. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
10. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
[TBL] [Abstract][Full Text] [Related]
11. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
Zhao XD; Zhang Y; He SR; Yang L
Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
[TBL] [Abstract][Full Text] [Related]
12. Ovarian carcinoma: the role of chemotherapy.
Thigpen JT; Vance RB; Lambuth BW
Semin Oncol; 1988 Jun; 15(3 Suppl 3):16-23. PubMed ID: 3293214
[TBL] [Abstract][Full Text] [Related]
13. Rationale for maintenance or consolidation therapy in ovarian cancer.
Markman M
Clin Adv Hematol Oncol; 2003 Mar; 1(3):176-8. PubMed ID: 16224399
[TBL] [Abstract][Full Text] [Related]
14. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
[TBL] [Abstract][Full Text] [Related]
15. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
17. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
Grossi F; Aita M; Follador A; Defferrari C; Brianti A; Sinaccio G; Belvedere O
Oncologist; 2007 Apr; 12(4):451-64. PubMed ID: 17470688
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
19. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
Stathopoulos GP; Malamos NA; Aravantinos G; Rigatos S; Christodoulou Ch; Stathopoulos J; Skarlos D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):123-8. PubMed ID: 17111119
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
